Takeda Pharmaceutical Company has put forward a fourth offer to acquire Shire, a day after the Irish biopharmaceutical company best known for ADHD drug Adderall rejected a previous offer.
The latest offer is for approximately £44.3bn, or £26 per share in new Takeda shares and £21 per share in cash─ a total of £47 per share.
Go deeper with GlobalData
The offer made the previous day was for £46.50 per share, comprised of £17.75 in cash and £28.75 of new Takeda shares.
The two other rejected offers were for £41bn and £43bn respectively. The most recent offer is an increase of approximately 7% of the original proposal made on in March.
In a statement, Japan-based Takeda said: “Takeda believes that the improved proposal represents a highly compelling opportunity for Shire shareholders, which reflects a further increase in value and a material increase in the cash component of the consideration mix. On completion of the proposed acquisition, Shire shareholders would hold a very meaningful stake in a leading global biopharmaceutical company and benefit from the material synergies expected to be derived from the acquisition.”
If successful, the deal would be the largest ever overseas acquisition by a Japanese company and would see Shire shareholders own approximately 49% of the enlarged Takeda.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIf the takeover happens, Takeda would be worth an estimated $80bn and the deal could significantly boost the company’s drug pipeline and presence in the US.
The new deal represents an 18% increase in the previous cash amount, a deal which Shire said ‘significantly undervalued the company and Shire’s growth prospects and pipeline’.
In a statement, Shire said: “Shire notes the announcement made by Takeda and confirms it has received a fourth proposal on 20 April 2018 regarding a possible offer for the company.
“The Board of Shire is considering its position with respect to the fourth proposal and will issue a further announcement in due course.”
Takeda also expressed that it wishes to extend the deadline by which it must announce a firm intention to make an offer, currently set for 2 April 2018, to allow for a ‘customary due diligence review’.
